Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Neoplasm, Residual"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 240
Tytuł:
Influence of Minimal Residual Disease at Day 15 of Induction Therapy on Survival of Children with Acute Lymphoblastic Leukemia.
Autorzy:
Samardžić-Predojević J; Children's Hospital, University Clinical Centre of the Republic of Srpska, Banja Luka, Republic of Srpska, Bosnia and Herzegovina; Faculty of medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina. .
Đurđević-Banjac B; Children's Hospital, University Clinical Centre of the Republic of Srpska, Banja Luka, Republic of Srpska, Bosnia and Herzegovina; Faculty of medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina. .
Malčić-Zanić D; Children's Hospital, University Clinical Centre of the Republic of Srpska, Banja Luka, Republic of Srpska, Bosnia and Herzegovina; Faculty of medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina.
Pokaż więcej
Źródło:
Acta medica academica [Acta Med Acad] 2023 Dec; Vol. 52 (3), pp. 153-160.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Child ; Humans ; Neoplasm, Residual ; Universities
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With Clinical Outcome in Adult B-Cell Acute Lymphoblastic Leukemia: A Real-World Study Based on 486 Patients.
Autorzy:
Liao H; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Jiang N; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Yang Y; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Zhang X; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Chen J; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Lai H; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Zheng Q; From the Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2023 Oct 01; Vol. 147 (10), pp. 1186-1195.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Humans ; Adult ; Neoplasm, Residual/diagnosis ; Flow Cytometry/methods ; Retrospective Studies ; Prognosis ; Acute Disease ; Recurrence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Molecular characterization of TCF3::PBX1 chromosomal breakpoints in acute lymphoblastic leukemia and their use for measurable residual disease assessment.
Autorzy:
Burmeister T; Department of Hematology, Oncology and Tumor Immunology, CVK, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany. .
Gröger D; Department of Hematology, Oncology and Tumor Immunology, CBF, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Gökbuget N; Medical Department 2, Goethe-Universität, Frankfurt, Germany.
Spriewald B; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
Starck M; I. Medical Department, München Klinik Schwabing, Munich, Germany.
Elmaagacli A; Department of Hematology, Oncology, Asklepios Klinik St. Georg, Hamburg, Germany.
Hoelzer D; Medical Department 2, Goethe-Universität, Frankfurt, Germany.
Keller U; Department of Hematology, Oncology and Tumor Immunology, CBF, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Schwartz S; Department of Hematology, Oncology and Tumor Immunology, CBF, Charité - Universitätsmedizin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Sep 13; Vol. 13 (1), pp. 15167. Date of Electronic Publication: 2023 Sep 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Adult ; Humans ; Basic Helix-Loop-Helix Transcription Factors ; Chromosome Breakpoints ; Drugs, Generic ; Neoplasm, Residual ; Real-Time Polymerase Chain Reaction ; Translocation, Genetic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of CD34 cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease.
Autorzy:
Wang Y; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Mo X; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Cheng Y; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Chen Y; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Lv M; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Wang F; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Yan C; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Han W; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Chen H; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Xu L; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Wang Y; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Zhang X; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Liu K; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Huang X; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.; Peking-Tsinghua Center for Life Sciences, Beijing, China.; Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.
Chang Y; Peking University People's Hospital and Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, People's Republic of China.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2023 Feb; Vol. 45 (1), pp. 72-81. Date of Electronic Publication: 2022 Oct 04.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Humans ; Neoplasm Recurrence, Local ; Transplantation, Homologous ; Neoplasm, Residual
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
De novo lymphoid blastic phase chronic myeloid leukemia: report and contemporary discussion.
Autorzy:
Hameed M; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Alnoamani M; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Marei M; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Tailor I; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Alshehri H; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Tashkandi SA; Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia.
Alswayyed A; Cytogenetics Laboratory, Department of Clinical Pathology, King Fahad Medical City, Riyadh, Saudi Arabia.
Alrajhi AM; Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, Saudi Arabia.; Department of Pharmacy Practice, College of Pharmacy, AlFaisal University, Riyadh, Saudi Arabia.
Zaidi SZA; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Motabi I; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
AlShehry N; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.
Alfayez M; College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.; Department of Hematology, King Fahad Medical City, Riyadh, Saudi Arabia.; Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 1259-1262.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Thrombocytopenia*
Humans ; Male ; Leukocytosis ; Prospective Studies ; Retrospective Studies ; Blast Crisis ; Neoplasm, Residual ; Chromosome Aberrations
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Dynamics of minimal residual disease defines a novel risk-classification and the role of allo-HSCT in adult Ph-negative B-cell acute lymphoblastic leukemia.
Autorzy:
Cai Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu Y; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Tang B; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wu Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Wang Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Lin R; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Xu X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Huang Z; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ou J; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Li X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu X; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Liu Q; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zhou H; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (13), pp. 3181-3190. Date of Electronic Publication: 2022 Sep 13.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adult ; Humans ; Neoplasm, Residual/diagnosis ; Philadelphia Chromosome ; Prognosis ; Acute Disease ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Monoclonal antibodies: new chance in the management of B-cell acute lymphoblastic leukemia.
Autorzy:
Shi Z; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Zhu Y; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Zhang J; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Chen B; Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 642-652.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Antineoplastic Agents, Immunological*/therapeutic use
Burkitt Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Antibodies, Monoclonal/therapeutic use ; Humans ; Inotuzumab Ozogamicin ; Neoplasm, Residual
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Association of minimal residual disease with clinical outcomes in Philadelphia chromosome positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era: A systemic literature review and meta-analysis.
Autorzy:
Zhang W; Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
Jang E; West China School of Medicine, Sichuan University, Chengdu, Sichuan Province, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Aug 26; Vol. 16 (8), pp. e0256801. Date of Electronic Publication: 2021 Aug 26 (Print Publication: 2021).
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Philadelphia Chromosome*
Neoplasm, Residual/*epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*epidemiology
Protein Kinase Inhibitors/*therapeutic use
Humans ; Immunotherapy/trends ; Neoplasm, Residual/complications ; Neoplasm, Residual/genetics ; Neoplasm, Residual/pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Prognosis ; Progression-Free Survival
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
High-throughput sequencing of immunoglobulin heavy chain for minimal residual disease detection in B-lymphoblastic leukemia.
Autorzy:
Correia RP; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Puga RD; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Muto NH; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Lee MLM; Grupo de Apoio ao Adolescente e a Criança com Câncer, São Paulo, Brazil.
Torres DC; Bone Marrow Transplantation Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Hassan R; Bone Marrow Transplantation Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.
Bacal NS; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Centro de Hematologia de São Paulo, São Paulo, Brazil.
Hamerschlak N; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Campregher PV; Departments of Clinical Pathology Laboratory, Hematology and Hemotherapy, Research Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2021 Aug; Vol. 43 (4), pp. 724-731. Date of Electronic Publication: 2021 Jan 04.
Typ publikacji:
Journal Article
MeSH Terms:
Immunoglobulin Heavy Chains/*genetics
Neoplasm, Residual/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
High-Throughput Nucleotide Sequencing ; Humans ; Neoplasm, Residual/diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
How I investigate minimal residual disease in acute lymphoblastic leukemia.
Autorzy:
Correia RP; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Bento LC; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
de Sousa FA; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Barroso RS; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Campregher PV; Clinical Pathology Laboratory, Molecular Genetics Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Bacal NS; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Centro de Hematologia de São Paulo, São Paulo, Brazil.
Pokaż więcej
Źródło:
International journal of laboratory hematology [Int J Lab Hematol] 2021 Jun; Vol. 43 (3), pp. 354-363. Date of Electronic Publication: 2021 Jan 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Neoplasm, Residual/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Animals ; B-Lymphocytes/pathology ; Flow Cytometry/methods ; Gene Fusion ; Gene Rearrangement ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Immunoglobulin G/genetics ; Neoplasm, Residual/genetics ; Neoplasm, Residual/pathology ; Polymerase Chain Reaction/methods ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Receptors, Antigen, T-Cell/genetics ; T-Lymphocytes/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Outcomes of blinatumomab based therapy in children with relapsed, persistent, or refractory acute lymphoblastic leukemia: a multicenter study focusing on predictors of response and post-treatment immunoglobulin production.
Autorzy:
Essa MF; Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.; King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia.
Abdellatif R; Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Elimam N; King Abdullah International Medical Research Center, National Guard Health Affairs, Riyadh, Saudi Arabia.; Department of Oncology, Princess Noorah Oncology Center, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Ballourah W; Department of Pediatric Hematology/Oncology, Comprehensive Cancer Center, King Fahd Medical City, Riyadh, Saudi Arabia.
Alsudairy R; Department of Pediatric Hematology/Oncology, King Abdullah Specialist Children's Hospital, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Alkaiyat M; Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Alsultan A; Department of Oncology, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.; Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.; Oncology Center, King Saud University Medical City, Riyadh, Saudi Arabia.
Jastaniah W; Department of Oncology, King Faisal Specialist Hospital & Research Center (Gen.Org.), Jeddah, Saudi Arabia.
Pokaż więcej
Źródło:
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2022 Oct; Vol. 39 (7), pp. 613-628. Date of Electronic Publication: 2022 Apr 23.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Epstein-Barr Virus Infections*
Lymphoma, B-Cell*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Antibodies, Bispecific ; Biomarkers ; Child ; Herpesvirus 4, Human ; Humans ; Immunoglobulin G ; Neoplasm, Residual
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Residence in a Latinx enclave and end-induction minimal residual disease positivity among children with acute lymphoblastic leukemia.
Autorzy:
Muñiz JP; Department of Internal Medicine and Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Woodhouse JP; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Hughes AE; Department of Population and Data Sciences and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Pruitt SL; Department of Population and Data Sciences and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Rabin KR; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Scheurer ME; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Lupo PJ; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Schraw JM; Center for Epidemiology and Population Health, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.; Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas, USA.; Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas, USA.
Pokaż więcej
Źródło:
Pediatric hematology and oncology [Pediatr Hematol Oncol] 2022 Oct; Vol. 39 (7), pp. 650-657. Date of Electronic Publication: 2022 Mar 09.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/epidemiology
Child ; Humans ; Incidence ; Neoplasm, Residual ; Texas
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India.
Autorzy:
Sharma P; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Rana S; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Virk H; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Sachdeva MUS; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Sharma P; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Varma N; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Jain R; Pediatric Hematology/Oncology Unit, Department of Pediatric Medicine, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Bansal D; Pediatric Hematology/Oncology Unit, Department of Pediatric Medicine, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Trehan A; Pediatric Hematology/Oncology Unit, Department of Pediatric Medicine, Advanced Pediatric Center, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Khadwal AR; Adult Clinical Hematology Unit, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Malhotra P; Adult Clinical Hematology Unit, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Sreedharanunni S; Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2474-2478. Date of Electronic Publication: 2021 May 24.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/epidemiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Cohort Studies ; Fusion Proteins, bcr-abl/genetics ; Gene Fusion ; Humans ; India/epidemiology ; Neoplasm, Residual/genetics
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Autorzy:
Wen J; Department of Pediatric Hematology, Caihong Hospital of Xianyang, Xi'an, People's Republic of China.
Zhou M; Department of Hematology, Chengdu Women and Children's Central Hospital, Chengdu, People's Republic of China.
Shen Y; Department of Hematology, Children's Hospital of Chongqing Medical University, Yuzhong District, Zhongshan 2nd Road, Chongqing, 400014, People's Republic of China.; Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, People's Republic of China.
Long Y; Department of Pediatrics, The Second Affiliated Hospital of Guizhou Medical University, Kaili, People's Republic of China.
Guo Y; Department of Hematology, Children's Hospital of Chongqing Medical University, Yuzhong District, Zhongshan 2nd Road, Chongqing, 400014, People's Republic of China.; National Clinical Research Center for Child Health and Disorders, Chongqing, People's Republic of China.; China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing, People's Republic of China.
Song L; Department of Pharmacy, Children's Hospital of Chongqing Medical University, Chongqing, People's Republic of China.; Chongqing Key Laboratory of Pediatrics, Chongqing, People's Republic of China.
Xiao J; Department of Hematology, Children's Hospital of Chongqing Medical University, Yuzhong District, Zhongshan 2nd Road, Chongqing, 400014, People's Republic of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Aug 06; Vol. 22 (1), pp. 859. Date of Electronic Publication: 2022 Aug 06.
Typ publikacji:
Journal Article
MeSH Terms:
Burkitt Lymphoma*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Child ; Female ; Humans ; Male ; Neoplasm, Residual/genetics ; Prognosis ; Prospective Studies ; Remission Induction
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ectopic expression of a combination of 5 genes detects high risk forms of T-cell acute lymphoblastic leukemia.
Autorzy:
Peng LJ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhou YB; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Geng M; Department of Oncology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Bourova-Flin E; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; UMR 5309, CNRSINSERM U1209Université Grenoble-Alpes/Institute for Advanced Biosciences, La Tronche, France.
Chuffart F; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; UMR 5309, CNRSINSERM U1209Université Grenoble-Alpes/Institute for Advanced Biosciences, La Tronche, France.
Zhang WN; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wang T; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gao MQ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xi MP; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cheng ZY; Jingjie PTM Biolab (Hangzhou) Co., Ldt, Hangzhou, China.
Zhang JJ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Liu YF; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen B; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Khochbin S; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; UMR 5309, CNRSINSERM U1209Université Grenoble-Alpes/Institute for Advanced Biosciences, La Tronche, France. .
Wang J; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .
Rousseaux S; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; UMR 5309, CNRSINSERM U1209Université Grenoble-Alpes/Institute for Advanced Biosciences, La Tronche, France. .
Mi JQ; Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; Laboratory of Molecular Pathology, Pôle de Recherches Sino-Français en Science du Vivant Et Génomique, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. .
Pokaż więcej
Źródło:
BMC genomics [BMC Genomics] 2022 Jun 24; Vol. 23 (1), pp. 467. Date of Electronic Publication: 2022 Jun 24.
Typ publikacji:
Journal Article
MeSH Terms:
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Adult ; Ectopic Gene Expression ; Humans ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/genetics ; Prognosis ; T-Lymphocytes/pathology ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
Autorzy:
Hupp MM; From the Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis (Hupp, Linden).
Bashleben C; College of American Pathologists, Northfield, Illinois (Bashleben, Long).
Cardinali JL; Special Hematology, Hartford Hospital, Hartford, Connecticut (Cardinali).
Dorfman DM; The Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dorfman).
Karlon W; The Departments of Pathology and Laboratory Medicine, University of California, San Francisco (Karlon).
Keeney M; London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada (Keeney).
Leith C; The Department of Pathology and Laboratory Medicine, University of Wisconsin Hospital and Clinics, Madison (Leith).
Long T; College of American Pathologists, Northfield, Illinois (Bashleben, Long).
Murphy CE; Summit Pathology, Fort Collins, Colorado (Murphy).
Pillai V; the Department of Pathology and Laboratory Medicine, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania (Pillai).
Rosado FN; The Department of Pathology and Laboratory Services, University of Texas Southwestern Medical Center, Dallas (Rosado).
Seegmiller AC; The Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee (Seegmiller).
Linden MA; From the Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis (Hupp, Linden).
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2021 Mar 01; Vol. 145 (3), pp. 336-342.
Typ publikacji:
Journal Article
MeSH Terms:
Laboratory Proficiency Testing/*standards
Multiple Myeloma/*diagnosis
Neoplasm, Residual/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Accreditation ; American Medical Association ; Flow Cytometry ; Follow-Up Studies ; Humans ; Immunophenotyping ; Multiple Myeloma/pathology ; Neoplasm, Residual/pathology ; Pathologists ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Surveys and Questionnaires ; United States
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Autorzy:
Li XY; Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Li JQ; Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Luo XQ; The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510080, China.
Wu XD; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Sun X; Guangzhou Women and Children's Medical Center, Guangzhou, 510623, China.
Xu HG; Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Li CG; Shenzhen Children's Hospital, Shenzhen, 518038, China.
Liu RY; Huizhou Municipal Central People's Hospital, Huizhou, 516001, China.
Sun XF; Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Chen HQ; The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
Lin YD; Guangdong General Hospital, Guangzhou, 510080, China.
Li CK; Hong Kong Children Hospital and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, 999077, China.
Fang JP; Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. .; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2021 Jan 13; Vol. 21 (1), pp. 59. Date of Electronic Publication: 2021 Jan 13.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasm Recurrence, Local/*mortality
Neoplasm, Residual/*mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*mortality
Adolescent ; Child ; Child, Preschool ; Cyclophosphamide/administration & dosage ; Cytarabine/administration & dosage ; Daunorubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Infant ; Male ; Mercaptopurine/administration & dosage ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Neoplasm, Residual/drug therapy ; Neoplasm, Residual/pathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Prednisone/administration & dosage ; Prognosis ; Remission Induction ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A challenging case of an adolescent and young adult patient with high-risk acute lymphoblastic leukemia: the need for a multidisciplinary approach: a case report.
Autorzy:
Kranjčec I; Department of Oncology and Hematology, Children's Hospital Zagreb, Klaićeva 16, 10000, Zagreb, Croatia. .
Matijašić N; Department of Oncology and Hematology, Children's Hospital Zagreb, Klaićeva 16, 10000, Zagreb, Croatia.
Abdović S; Division of Nephrology, Department of Pediatrics, Children's Hospital Zagreb, Zagreb, Croatia.
Hižar Gašpar I; Department of Pediatrics, Children's Hospital Zagreb, Zagreb, Croatia.
La Grasta Sabolić L; Department of Pediatric Endocrinology, Diabetes and Metabolism, University Hospital Center Sestre milosrdnice, Zagreb, Croatia.
Jadrijević-Cvrlje F; Department of Oncology and Hematology, Children's Hospital Zagreb, Klaićeva 16, 10000, Zagreb, Croatia.
Pokaż więcej
Źródło:
Journal of medical case reports [J Med Case Rep] 2022 Apr 11; Vol. 16 (1), pp. 147. Date of Electronic Publication: 2022 Apr 11.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Hemosiderosis*/drug therapy
Hemosiderosis*/etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Humans ; Iron/therapeutic use ; Male ; Neoplasm, Residual/drug therapy ; Neoplasm, Residual/etiology ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
Autorzy:
Arumugam JR; Departments of Oncopathology, Cancer Institute (Women's India Association), Chennai, India.
Bommannan K; Departments of Oncopathology, Cancer Institute (Women's India Association), Chennai, India.
Radhakrishnan V; Departments of Oncopathology, Cancer Institute (Women's India Association), Chennai, India.
Sagar TG; Departments of Oncopathology, Cancer Institute (Women's India Association), Chennai, India.
Sundersingh S; Departments of Oncopathology, Cancer Institute (Women's India Association), Chennai, India.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Mar; Vol. 63 (3), pp. 644-652. Date of Electronic Publication: 2021 Nov 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Child ; Flow Cytometry/methods ; Humans ; Immunomodulation ; Immunophenotyping ; Neoplasm, Residual/diagnosis
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Protocol for ICiCLe-ALL-14 (InPOG-ALL-15-01): a prospective, risk stratified, randomised, multicentre, open label, controlled therapeutic trial for newly diagnosed childhood acute lymphoblastic leukaemia in India.
Autorzy:
Das N; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.
Banavali S; Department of Pediatric Oncology, Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, 40094, India.
Bakhshi S; Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, 110029, India.
Trehan A; Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Center, Postgraduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Radhakrishnan V; Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, 600020, India.
Seth R; Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India.
Arora B; Department of Pediatric Oncology, Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, 40094, India.
Narula G; Department of Pediatric Oncology, Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, 400012, India.; Homi Bhabha National Institute, Mumbai, Maharashtra, 40094, India.
Sinha S; Department of Statistics, Tata Medical Center, Kolkata, West Bengal, 700160, India.
Roy P; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.
Gogoi MP; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.
Chatterjee S; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.
Abraham B; Tata Consultancy Services, Kolkata, West Bengal, 700135, India.
Das P; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.
Saha V; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India.; Department of Pediatric Oncology, Tata Medical Center, Kolkata, West Bengal, 700160, India.; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M20 4BX, UK.
Krishnan S; Clinical Research Unit, Tata Translational Cancer Research Centre, Tata Medical Centre, 14 MAR (E-W), New Town, Kolkata, West Bengal, 700160, India. .; Department of Pediatric Oncology, Tata Medical Center, Kolkata, West Bengal, 700160, India. .; Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M20 4BX, UK. .
Pokaż więcej
Źródło:
Trials [Trials] 2022 Jan 31; Vol. 23 (1), pp. 102. Date of Electronic Publication: 2022 Jan 31.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Neoplasm Recurrence, Local*
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/genetics
Humans ; Multicenter Studies as Topic ; Neoplasm, Residual ; Prospective Studies ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 240

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies